Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 2/20 | 0.37 |
| ▸ | PAK3 | O75914 | 2/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.35 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.35 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.35 |
| ▸ | CDK1 | P06493 | 5/20 | 0.35 |
| ▸ | CDK4 | P11802 | 5/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.35 |
| ▸ | CCND1 | P24385 | 5/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.35 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | CDK7 | P50613 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 5/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041861 | 0.80 | MAP4K1 (0.39) | PKN1CCNT1CDK1CDK4CCNA2 | |
| SCHEMBL15041854 | 0.78 | GCK (0.44) | ACVR1CCNT1CDK1CDK4CCNA2 | |
| SCHEMBL13553882 | 0.77 | CDK4 (0.41) | PAK1PKN1CCNT1CDK1CDK4 | |
| SCHEMBL15041528 | 0.75 | STK3 (0.40) | ACVR1PAK1PKN1CCNT1CDK1 | |
| SCHEMBL15041662 | 0.74 | PKN1 (0.43) | ACVR1PAK3PAK1PAK2PKN1 | |
| SCHEMBL13553735 | 0.74 | PTK2 (0.40) | ACVR1PAK3PAK1PAK2PKN1 | |
| SCHEMBL15785315 | 0.74 | PAK4 (0.42) | PKN1TNK2MAP4K1PAK4WEE1 | |
| SCHEMBL14682036 | 0.73 | MAP4K1 (0.41) | PKN1CCNT1CDK1CDK4CCNA2 | |
| SCHEMBL15785269 | 0.72 | TNK2 (0.41) | PAK1PKN1CCNT1CDK1CDK4 | |
| SCHEMBL15041699 | 0.72 | AURKA (0.43) | ACVR1PAK1PKN1CDK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | ACVR1 4752/4885PAK3 6/4885PAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.